🤝 Bristol Myers Squibb is set to acquire 2seventy bio in an all-cash transaction valued at approximately $286 million. After accounting for 2seventy bio’s cash reserves, the net acquisition cost for BMS stands at around $102 million. The deal is expected to close in H2'25. 👉 This acquisition gives BMS full control of Abecma (idecabtagene vicleucel), a BCMA-targeted CAR-T cell therapy indicated for the treatment of adult patients with R/R multiple myeloma after two or more p

Since March is Multiple Myeloma Awareness Month, we at Oncofocus have created an informative infographic highlighting the current treatment options and emerging therapies for Multiple Myeloma.